Eravacycline Combination Therapy for MRAB

Launched by FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL · Feb 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a combination treatment using two antibiotics, Eravacycline and Polymyxin, to help patients with pneumonia caused by a type of bacteria called Acinetobacter baumannii, which is resistant to many other antibiotics. The main goal is to find out how effective and safe this treatment is for people suffering from this serious lung infection.

To participate in the trial, individuals need to be at least 18 years old and diagnosed with pneumonia. They should be able to receive Eravacycline for at least four days and must have signed the consent form to join. During the study, participants will be monitored closely to check how well the treatment is working and to ensure their safety. However, pregnant or breastfeeding individuals and those with certain serious infections or medical conditions will not be eligible to take part. If you or someone you know is interested in this study, it could be a chance to help advance treatments for tough-to-treat infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ≥18 years old;
• • 2. Meets the diagnostic criteria for pneumonia specified by the Chinese Medical Association Respiratory Branch.
• • 3. CRAB is identified or predominant pathogenic bacteria, and drug sensitivity test indicates that Eravacycline is sensitive to the strain;
• • 4. Patients expected to receive Eravacycline for ≥4 days;
• • 5. Has already signed the informed consent
• Exclusion Criteria:
• • 1. Pregnant or lactating;
• • 2. Concurrent intracranial infection, urinary tract infection, or bloodstream infection;
• • 3. Individuals in a moribund state;
• • 4. The investigator believes there is any medical history, current condition, treatment, laboratory abnormalities, or other circumstances that may affect the trial results, interrupt the trial process (or the subject's inability to complete all trial requirements, operations, and visits), or increase the subject's risk with the experimental medication. Patients with terminal illnesses or evidence of immediately life-threatening diseases are excluded;
• • 5. Patients with a history of allergic reactions to tetracyclines or any excipients in the investigational drug formulation